Literature DB >> 6278057

Comparison of thymidine kinase activities indiced in cells productively infected with herpesvirus saimiri and herpes simplex virus.

R W Honess, P O'Hare, D Young.   

Abstract

The replication of unselected strains of herpesvirus saimiri (HVS) was sensitive to bromodeoxyuridine and bromovinyldeoxyuridine (BVdU) but insensitive to acycloguanosine (ACG), in contrast to the growth of herpes simplex virus (HSV) which was sensitive to all three analogues. Mutants of HVS resistant to bromodeoxyuridine and BVdU could be selected by growth in the presence of these inhibitors. Productive infections of owl monkey kidney or Vero cell cultures by unselected strains of HVS resulted in increases in a thymidine kinase (TK) activity which was deficient in cells infected with bromodeoxyuridine-resistant mutants of the virus. Induction of the virus enzyme promoted a net increase in the uptake and incorporation of exogenous labelled thymidine in the face of the progressive inhibition of the overall incorporation of [35S]methionine and [3H]uridine into productively infected cells. The TK induced in cells infected with HVS differed from the major activity of uninfected cells and resembled that encoded by HSV in its capacity to phosphorylate iododeoxyuridine and in the sensitivity of all the thymidine phosphorylating activity to competition by BVdU. However, in contrast to the HSV TK, which phosphorylated deoxycytidine and iododeoxycytidine relatively efficiently and was sensitive to ACG, the HVS enzyme did not phosphorylate deoxycytidine or iododeoxycytidine and was insensitive to ACG. Whilst HVS, therefore, shares the characteristic of other members of the herpesvirus group of inducing a novel TK, the properties of the HVS-induced enzyme differ significantly from the enzyme of the prototype herpesvirus, HSV. The properties of the HVS TK are nonetheless sufficiently distinct from those of the uninfected cell to provide a possible basis for selective antiviral chemotherapy based on preferential phosphorylation of nucleoside analogues such as BVdU by infected cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6278057     DOI: 10.1099/0022-1317-58-2-237

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  10 in total

1.  Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir.

Authors:  E A Gustafson; R F Schinazi; J D Fingeroth
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Characterization of the Epstein-Barr virus-encoded thymidine kinase expressed in heterologous eucaryotic and procaryotic systems.

Authors:  E Littler; J R Arrand
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

3.  Characterization of an Epstein-Barr virus-induced thymidine kinase.

Authors:  M de Turenne-Tessier; T Ooka; G de The; J Daillie
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

4.  Isolation and characterization of monoclonal antibodies to structural and nonstructural herpesvirus saimiri proteins.

Authors:  R E Randall; C Newman; R W Honess
Journal:  J Virol       Date:  1984-12       Impact factor: 5.103

5.  Identification of a subset of herpesvirus saimiri polypeptides synthesized in the absence of virus DNA replication.

Authors:  P O'Hare; R W Honess
Journal:  J Virol       Date:  1983-04       Impact factor: 5.103

6.  Genome structure and virion polypeptides of the primate herpesviruses Herpesvirus aotus types 1 and 3: comparison with human cytomegalovirus.

Authors:  A Ebeling; G Keil; B Nowak; B Fleckenstein; N Berthelot; P Sheldrick
Journal:  J Virol       Date:  1983-02       Impact factor: 5.103

7.  Activity and mechanism of action of HDVD, a novel pyrimidine nucleoside derivative with high levels of selectivity and potency against gammaherpesviruses.

Authors:  N Coen; U Singh; V Vuyyuru; J J Van den Oord; J Balzarini; S Duraffour; R Snoeck; Y C Cheng; C K Chu; G Andrei
Journal:  J Virol       Date:  2013-01-23       Impact factor: 5.103

8.  Phosphorylation of acyclovir in vitro in activated Burkitt somatic cell hybrids.

Authors:  A K Datta; J S Pagano
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

Review 9.  Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

10.  In vitro growth characteristics of bovine herpesvirus 4 (BHV-4) as revealed by indirect immunofluorescence assay with monoclonal antibodies and polyvalent antisera.

Authors:  H R Augsburger; A E Metzler
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.